Bimekizumab: IL-17A and F inhibitor for tx of PsA - BE OPTIMAL trial reached primary endpoint: ACR50 44% vs. placebo Efficacy as early as 2 weeks No MACE, uveitis, IBD, deaths @RheumNow #EULAR2022 ABST#LB0001 cc:@doctorRBC : https://t.co/wgeBsfdQcL

Prof Hoi @alberta_hoi Anti-Sm in SLE. Present in 17%. Assoc severe disease activity, "classic" SLE manifestations, specific serologic and proteomic profile. Argues for Sm+ SLE being a specific subset (or even a "different" disease?) #EULAR2022 POS0774. cc: @RichardPAConway https://t.co/cwp6q4kouz

#Bestinclass Recurrent #PMR RCT of #sarilumab v placebo. Nearly doubles sustained remission but maybe attenuating effect - flare difference over time? N=118. 🤷‍♀️ Dunno who I would use it in yet. LB0006 @RheumNow @eular_org #EULAR2022 @Janetbirdope

SELECT-AXIS 1 trial of upadacitinib in active #AS with an inadequate resp to prior biologic - pivotal phase 2/3 RCT of 420 AS pts (Dz dur 7.7 yrs; 83% B27+) showed better ASAS40 at wk 14 w/ UPA vs PBO (45% vs 18%; P<0.0001) #EULAR2022 POS0306 https://t.co/JmreAOqnqh https://t.co/pTFeAzWUYU

• https://bit.ly/3RjuJHh

Solving Still’s Disease Still's disease is the most common rheumatic cause of unknown fever in adults. This series covers the definition, history, epidemiology, key manifestations and labs, diagnostic criteria, and more. https://t.co/YqpSW6T3El https://t.co/vwehTCm4aN

• https://bit.ly/3PeIXr9

Allopurinol Safety in CKD Patients A study in the Annals of Internal Medicine reports chronic kidney disease (CKD) patients can be safely treated with allopurinol without an increased risk of mortality. https://t.co/qUQmuZedJq https://t.co/u2Ntjd1oio

• https://bit.ly/3uyAhUm

QD Clinic - Stills (or Not) MAS off of Tocilizumab https://t.co/YGEifF5X8K https://t.co/719RjYzbE3

• https://bit.ly/3ympnSV

CDC: Immunocompromised account for 12.2% of all COVID-19 hospitalizations, with an increased risk of ICU (aOR=1.26) and death (aOR = 1.34), even if vaccinated (aOR 1.40; aOR = 1.87). In immunocompromised, death rate was not affected by vaccination. https://t.co/PVRnOPb9gX https://t.co/W2S9eb1cOo

• https://bit.ly/3AwUXQw

Here's a reference for the Salmon-pink skin rashes in adult-onset Still's disease; distinctive in color (faint, salmon-pink), distribution (trunk, neck extremities), and evanescence (comes and goes within the same day). These are not static eruptions! https://t.co/BgzyQeiLyW https://t.co/c3aolVfpav

• https://bit.ly/3uy2KcZ

Study of 184 #SLE pts shows that major infections in SLE results in a 7 fold increased risk of a major lupus flare. Abst# OP0143 #EULAR2022 #MedTwitter https://t.co/xUkQmwoeni

Single center comparison of MAS (n 18) to malignancy related mHLH (n = 16). Notable differences seen in platelet (lower in mHLH 29k v 50K), soluble IL-2R (6814 vs 27972), but more hepatomegaly (25% v 0). Less mortality with MAS (22 v 44%, p 0.18) https://t.co/gYdRfxDM2c https://t.co/ekMJfnzElC

• https://bit.ly/3yQmviM

Getting Real on PMR Dr. David Liew talks polymyalgia rheumatica and how our understanding has evolved over the years. #EULAR2022 https://t.co/DyVCxDVPE7 https://t.co/PF7zqxX7yk

• https://bit.ly/3NZTDJf

IL-18, Iike IL-1, is a produced by activation of the inflammasome. IL-18 is a potential bioimarker for #AOSD, closely linked to Dz activity & could be a Tx target, either as IL-18 binding protein (Tadekinig alfa) or mAb against IL-18 (phase 1b) https://t.co/ex231f27rg https://t.co/tjsra4blBi

• https://bit.ly/3yNaj20